Zanzalintinib and eribulin for advanced leiomyosarcoma and liposarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, zanzalintinib and eribulin, for people with advanced leiomyosarcoma or liposarcoma that has progressed after prior treatment. The goal is to see if this combination can help shrink or slow the growth of these sarcomas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of sarcoma called leiomyosarcoma or liposarcoma that has spread or cannot be removed by surgery.
- You have had at least 1 but no more than 4 previous treatments for your sarcoma.
- Your tumor can be seen and measured on an imaging scan (like a CT or MRI).
- You are 18 years or older and are in generally good health (able to do daily activities).
- Your blood counts and organ function (kidney, liver) are within a certain range, and you do not have untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (zanzalintinib, ipilimumab, and nivolumab) for people with soft tissue sarcoma that has spread. The goal is to see if this combination can shrink or slow the cancer.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial tests an experimental drug called XL092 (zanzalintinib) for people with advanced leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is a type of targeted therapy that may stop cancer growth.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
Hear when a new Advanced Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.